Helena Earl

Helena Earl has been Professor Emeritus of Clinical Cancer Medicine in the Department of Oncology, University of Cambridge since January 2019. Previously, she was appointed as a Senior Lecturer at the University of Birmingham (1992) where she was Director of the Birmingham Cancer Clinical Trials Unit, moving to the University of Cambridge in 1996. She has co-led multi-centre randomised phase III clinical trials in breast cancer (NEAT, tAnGo, Neo-tAnGo, ARTemis, PERSEPHONE, and PARTNER). She has authored over 200 peer reviewed papers, and held collaborative grant funding from Cancer Research UK, and the NIHR HTA, with pharmaceutical partnership funding from Roche, Astra Zeneca, Sanofi-Aventis, and Eli Lilly.

More recently she has been involved in the Lancet Breast Cancer Commission (2021-4): tackling a global health, gender, and equity challenge, in line with her interests in global oncology, value-based healthcare for cancer and cost-effective cancer therapies. She is a member of the Optimal Cancer Care Alliance and Common-Sense Oncology and has recently contributed to the Cancer Care Through De-escalation Studies Symposium, at NKI, Amsterdam (March 2026). She has served as the honorary President of ACP/UKSMO since January 2022.